Rocket Doctor AI Delivers 3625 U.S. Patient Visits in July and August

Important Disclosures:

1. Rocket Doctor AI Inc. is a billboard sponsor of Streetwise Reports. The company pays a monthly sponsorship fee of US$3,000–US$6,000 for banner advertising and an enhanced company profile page. Streetwise Reports’ editorial content is fully independent and is not influenced by sponsorship.
2. As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of Rocket Doctor AI Inc.
3. Jordan Nova wrote this article for Streetwise Reports LLC and provides services to Streetwise Reports as an employee. 
4. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company. 
5. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

For additional disclosures, please click here.

1. Disclosure for the quote from the Stewart Thomson article published on March 17, 2026

1. For the quoted article (published on March 17, 2026), Rocket Doctor AI Inc. has paid Street Smart, an affiliate of Streetwise Reports, US$2,500.

2. Author Certification and Compensation: Stewart Thomson was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Thomson is a retired Canadian financial advisor who has passed the Canadian Securities Course as well as additional technical analysis courses that were mandated by his former employer and approved by Ontario regulatory bodies. For the past 15 years, he has been editing and writing numerous financial newsletters that have a strong focus on charts.  The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed.

2. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.

Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA) posted 3,625 completed U.S. patient visits during July and August 2026, in a recent press release. That total reached 93 percent of the 3,911 visits recorded across the entire second quarter.

The strong two-month run comes as Medicare telehealth rules remain extended through the end of 2027. Retail investors are watching how the company converts rising visit volume into recognized revenue while it scales its platform.

Rocket Doctor AI Inc. (AIDR:CSE; AIRDF:OTC; 939:FRA) distinguishes between in-network and out-of-network patients. In-network visits require both the patient and physician to be enrolled with the payer for claims to qualify for payment. Out-of-network visits are accepted to grow adoption, and any amounts recovered from out-of-network claims are recognized as revenue only when cash is received.

Why the Visit Growth Matters Now

U.S. operational metrics for the first two months of the third quarter of 2026, with completed patient visits reaching 3,625 for the two-month period ended Aug. 31 show the company is maintaining momentum after its second-quarter results.

Clinical hours reached 1,555 in the same period, or 78 percent of the prior quarter total. Certain revenues are recorded on a cash basis, so a timing lag exists between visits and revenue recognition.

Company Advantage in Virtual Care Delivery

The platform was built by physicians for physicians. This design supports independent practice management and helps address access gaps, especially in rural areas.

The company is also moving into value-based primary care agreements that assign patient panels and generate recurring per-member-per-month payments instead of one-off visit fees.

Key Assets and Next Catalysts

Rocket Doctor AI's September 2026 investor overview identified Florida and Texas as part of its state expansion pipeline, covering roughly 17.8 million Medicare and Medicaid lives. In California, New York, and Maryland, the company has 81 signed physicians, with 31 already active and 50 in credentialing.

Physician capacity stands at three times the current active levels. The first value-based agreement covers an initial panel of 30,000 members and spans Commercial HMO, PPO, Medicare Advantage, D-SNP, and Medi-Cal plans.

Broader Telehealth Sector Timing

According to a February 26 update from the Centers for Medicare & Medicaid Services, Medicare beneficiaries can receive telehealth services anywhere in the United States and territories through December 31, 2027. Rural Health Clinics and Federally Qualified Health Centers can continue billing for non-behavioral health services delivered remotely, and audio-only options remain available.

An August 4 report from Johns Hopkins Medicine noted that the health system has conducted nearly 3 million remote visits since March 2020. The report highlighted telemedicine's use in primary care, specialty consultations, and chronic condition management.

Analyst Views and Valuation Context¹

Technical analyst Stewart Thomson wrote on March 17 that the platform expands healthcare access and rated the stock a Strong Speculative Buy with price targets of CA$0.80 short-term, CA$1.00 medium-term, and CA$1.60 long-term.

On June 11, Fundamental Research Corp. analyst Sid Rajeev reiterated a Buy rating and CA$1.55 target, citing U.S. expansion and rising patient volumes as drivers for future improvement.

Share Structure and Near-Term Events²

Rocket Doctor AI Inc. has a market capitalization of approximately CA$59.61 million and 101.55 million shares outstanding. The 52-week range is CA$0.50 to CA$0.98.

Management and insiders own 4.24 percent of the shares. 

Key Investor Takeaways

• 3,625 U.S. visits in two months equal 93 percent of the prior full quarter, showing sustained operational momentum.
• Medicare telehealth flexibilities extended through 2027 provide a supportive regulatory backdrop for continued growth.
• Value-based agreements shift revenue toward recurring per-member-per-month payments and assign dedicated patient panels.
• Expansion pipeline targets 17.8 million covered lives in Florida and Texas, while physician capacity remains three times current active levels.
• Two analysts have issued or reiterated Buy or Strong Speculative Buy ratings, with price targets ranging from CA$0.80 to CA$1.60.¹
• Out-of-network visits build volume and support future payer contracting, even though revenue is recognized only on cash receipt.

Common Questions from Investors

What drove the 3,625 visits in July and August?

The company reported continued U.S. platform adoption and physician activity that produced 93 percent of the prior quarter's total in just two months.

How does the company recognize revenue from out-of-network visits?

Out-of-network revenue is recorded only when cash is actually received because collection is uncertain. In-network claims follow standard payer enrollment rules.

What is the size of the value-based care agreement?

The initial California agreement covers 30,000 covered members under a recurring per-member-per-month model that includes multiple Medicare and commercial lines.

Which states are next for expansion?

Florida and Texas represent the near-term pipeline with roughly 17.8 million Medicare and Medicaid covered lives targeted through existing payer relationships.

Rocket Doctor AI continues to balance early-stage U.S. adoption strategies with longer-term payer contracting and value-based care models. Investors should monitor quarterly visit trends, network conversion rates, and progress on the Florida and Texas pipeline for further clarity on revenue timing.